Compare RNXT & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNXT | UG |
|---|---|---|
| Founded | 2012 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 32.9M |
| IPO Year | 2021 | N/A |
| Metric | RNXT | UG |
|---|---|---|
| Price | $0.88 | $6.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 214.1K | 14.1K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 11.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | $928,000.00 | ★ $10,060,322.00 |
| Revenue This Year | $2,795.35 | N/A |
| Revenue Next Year | $272.69 | N/A |
| P/E Ratio | ★ N/A | $14.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.70 | $5.58 |
| 52 Week High | $1.69 | $11.98 |
| Indicator | RNXT | UG |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 44.73 |
| Support Level | $0.83 | $5.95 |
| Resistance Level | $1.00 | $6.08 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 36.53 | 84.32 |
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.